In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1 to 50 of 380

TitleTypeExpected publication date
12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510]Technology appraisal guidance
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]Technology appraisal guidanceTBC
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer [TSID12065]Technology appraisal guidanceTBC
Abicipar pegol for treating wet age-related macular degeneration [ID1533]Technology appraisal guidanceTBC
Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]Technology appraisal guidance
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]Technology appraisal guidance
Advanced breast cancer: diagnosis and management (Partial update)NICE guideline
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]Technology appraisal guidance
Aggressive behaviour in people receiving NHS or social careQuality standard
Aggressive behaviour in people receiving NHS or social care: prevention and managementNICE guideline
Alcohol Use Disorders (update)NICE guidelineTBC
ALXN1840 for treating Wilson disease [ID6422]Technology appraisal guidanceTBC
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]Technology appraisal guidanceTBC
Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]Technology appraisal guidanceTBC
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]Highly specialised technologyTBC
Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis [ID6732 ]Technology appraisal guidanceTBC
Artificial intelligence (AI) technologies to assist histopathology for prostate cancer diagnosis [ID6684]Technology appraisal guidanceTBC
Artificial intelligence (AI) technologies to help detect prostate cancer on multiparametric (mp) MRIHealth technology evaluationTBC
Artificial Intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: Early Value AssessmentHealth technology evaluation
Artificial intelligence software to help detect and characterise colorectal polypsDiagnostics guidanceTBC
Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]Technology appraisal guidanceTBC
Asunercept for treating glioblastoma [ID1301]Technology appraisal guidanceTBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer [TSID10701]Technology appraisal guidanceTBC
Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]Technology appraisal guidanceTBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]Technology appraisal guidanceTBC
Atezolizumab with BCG before surgery (neoadjuvant) for treating non-muscle-invasive bladder cancer [ID6667]Technology appraisal guidanceTBC
Atogepant for treating migraine [ID6615]Technology appraisal guidance
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]Technology appraisal guidanceTBC
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]Technology appraisal guidanceTBC
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]Technology appraisal guidanceTBC
Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]Technology appraisal guidance
Avelumab for previously treated platinum-resistant ovarian cancer [ID1497]Technology appraisal guidanceTBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]Technology appraisal guidanceTBC
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]Technology appraisal guidanceTBC
Baloxavir marboxil for reducing direct transmission of influenza A or B in people 5 to 64 years [ID6552]Technology appraisal guidanceTBC
Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]Technology appraisal guidanceTBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]Technology appraisal guidance
Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]Technology appraisal guidanceTBC
Benralizumab for previously treated severe nasal polyps [ID1659]Technology appraisal guidanceTBC
Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]Technology appraisal guidanceTBC
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]Technology appraisal guidance
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537]Technology appraisal guidance
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]Technology appraisal guidance
Bipolar disorder: assessment and management (extraordinary review)NICE guidelineTBC
Bladder cancer: diagnosis and management (update)NICE guidelineTBC
Botulinum toxin type A for preventing episodic migraine [ID6450]Technology appraisal guidanceTBC
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]Technology appraisal guidanceTBC
Breast cancer guidelinesNICE guidelineTBC
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]Technology appraisal guidanceTBC
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All